2,0
9 okt 2011
Huidige werknemer
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht
Pluspunten
Excellent pipeline that has a lot of potential. The oncology, RA, and biotech portfolios are really making inroads and will have a significant impact on patient treatment.
Minpunten
Constant downsizing & restructuring leaves you always wondering when you'll be next to go. Pfizer still seems unprepared for Lipitor patent cliff.